sorafenib-sensitive PDGFR mutants [plasma membrane]

Stable Identifier
Set [DefinedSet]
Homo sapiens
Locations in the PathwayBrowser
Literature References
PubMed ID Title Journal Year
22665524 Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors

Heinrich, MC, Mariño-Enríquez, A, Presnell, A, Donsky, RS, Griffith, DJ, McKinley, A, Patterson, J, Taguchi, T, Liang, CW, Fletcher, JA

Mol. Cancer Ther. 2012
31723821 FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia

Lierman, E, Smits, S, Appleby, N, Conneally, E, Michaux, L, Vandenberghe, P

Hemasphere 2019
16645167 Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

Lierman, E, Folens, C, Stover, EH, Mentens, N, Van Miegroet, H, Scheers, W, Boogaerts, M, Vandenberghe, P, Marynen, P, Cools, J

Blood 2006
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!